Patented technology regarding a superior adjuvant with the active substance polysaccharide for oral/nasal vaccines against influenza and bird influenza, targeted to the aging population.

PHN032 is a fraction of polysaccharides extracted from a Chinese herb. Pharmacology and mechanism of action: Studies show that PHN032, as vaccine adjuvant, largely enhances mucosal immunization for IgA production as well as systematic immunization for both IgM and IgG production. Competitive niches: • Benefits the aging population as weak response to immunization is of concern. • Induces both mucosal and systematic immune responses. • The elicited mucosal immune response serves as the first line defense against foreign pathogens prior to the systematic responses. • Oral or nasal vaccines are easier to use than injectible vaccines. • Safer than cholera toxin subunit for similar applications. • Can be applied to other vaccines, and can be used in child populations.

Early Stage

The first US patent (patent number: 6,998,262 B2) of PHN032 has been granted as of June 2005 and more relevant patents (application number: 11/093,970) have been and will continue to be filed.

Licensing or partnering.